Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8598188
APP PUB NO 20120083503A1
SERIAL NO

13255550

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention relates to an antitumor agent comprising carboplatin and a combination drug of tegafur/gimeracil/oteracil potassium to be administered to a cancer patient selected according to an expression level of thymidylate synthase gene.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TAIHO PHARMACEUTICAL CO LTDCHIYODA-KU TOKYO 101-8444
KINKI UNIVERSITYHIGASHI-OSAKA-SHI OSAKA 577-8502

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Nakagawa, Kazuhiko Higashiosaka, JP 51 542
Okamoto, Isamu Higashiosaka, JP 3 13

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 3, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00